# Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)

> **NCT03490331** · PHASE1,PHASE2 · TERMINATED · sponsor: **Holostem s.r.l.** · enrollment: 1 (actual)

## Conditions studied

- Junctional Epidermolysis Bullosa

## Interventions

- **OTHER:** Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)

## Key facts

- **NCT ID:** NCT03490331
- **Lead sponsor:** Holostem s.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-19
- **Primary completion:** 2018-09-11
- **Final completion:** 2018-09-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** No patient ongoing (none completed the study). Changes to the viral vector ongoing.
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490331, "Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03490331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*